Moscow registry of patients with acromegaly: long-term results of observations
- Authors: Antsiferov M.B1, Alekseeva T.M1, Pronin V.S2
-
Affiliations:
- SBHCI “Endocrinological Dispensary" of Moscow Healthcare Department
- FSBEI APE “Russian Medical Academy of Postgraduate Education“ of RMH
- Issue: No 16 (2016)
- Pages: 62-66
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289271
- ID: 289271
Cite item
Open Access
Access granted
Abstract
The article presents data of recent retrospective analysis of electronic medical records of patients enrolled in the Moscow registry of patients with acromegaly. As of July 2016, there were 506patients with acromegaly in the Moscow registry, 52% of patients were treated with somatostatin analogues. 118 electronic medical records of patients, in whom octreotide was changed on lanreotide because of the inefficiency of previous treatment with somatostatin analogues, or significant side effects, were analyzed. The data on the efficacy and tolerability of lanreotide in patients previously treated with octreotide are presented.
Full Text
About the authors
M. B Antsiferov
SBHCI “Endocrinological Dispensary" of Moscow Healthcare Department
T. M Alekseeva
SBHCI “Endocrinological Dispensary" of Moscow Healthcare Department
Email: mamamarka@yandex.ru
MD, Prof, Head of the Department of Endocrinology
V. S Pronin
FSBEI APE “Russian Medical Academy of Postgraduate Education“ of RMHEndocrinology department
References
- Biermasz N.R., Pereira A.M., Smit J.W., Romijn J.A., Roelfsema F. Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. J. Clin. Endocrinol. Metab. 2005;90(5):2731-39.
- Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors Influencing Mortality in Acromegaly J. Clin. Endocrinol. Metab. 2004;89(2):667-74.
- Анциферов М.Б., Пронин В.С., Алексеева Т.М., Дорофеева Л.Г Опыт ведения Московского регистра больных акромегалией: возможности решения различных терапевтических задач. Фарматека. 2013;16:40-5.
- Chanson P., Salenave S. Acromegaly. Orphanet J. Rare Dis. 2008;3:17.
- Katznelson L., Atkinson J.L.D., Cook D.M., Ezzat S.Z., Hamrahian A.H., Miller K.K. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly - 2011 Update. Endocr. Pract. 2011;17(Supp. 4):1-44.
- Katznelson L., Atkinson J.L., Cook D.M., Ezzat S.Z., Hamrahian A.H., Miller K.K.; AACE Acromegaly Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly - 2011 update: executive summary. Endocr. Pract. 2011;17(4): 636-46.
- Дедов И.И., Мельниченко Г.А. Акромегалия: патогенез, клиника, диагностика, диффе ренциальная диагностика, методы лечения. Пособие для врачей. М., 2012. 80 c.
- Schloffer H. Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin. Wochenschr. 1907;20:621-24.
- Melmed S., Colao A., Barkan A., Molitch M., Grossman A.B., Kleinberg D., Clemmons D., Chanson P., Laws E., Schlechte J., Vance M.L., Ho K., Giustina A.; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 2009;94(5):1509-17.
- Mortini P., Barzaghi R., Losa M., Boari N., Giovanelli M. Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery. 2007;60(6):993-1002.
- Arosio M., Reimondo G., Malchiodi E., Berchialla P., Borraccino A., DeMarinis L., Pivonello R., Grottoli S., Losa M., Cannavö S., Minuto F., Montini M., Bondanelli M., De Menis E., Martini C., Angeletti G., Velardo A., Peri A., Faustini-Fustini M, Tita P., Pigliaru F., Borretta G., Scaroni C., Bazzoni N., Bianchi A., Appetecchia M., Cavagnini F., Lombardi G., Ghigo E., Beck-Peccoz P., Colao A., Terzolo M.; Italian Study Group of Acromegaly. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 2012;167:189-98.
- Florio T., Thellung S., Corsaro A., Bocca L., Arena S., Pattarozzi A., Villa V., Massa A., Diana F., Schettini D., Barbieri F., Ravetti J.L., Spaziante R., Giusti M., Schettini G. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin. Endocrinol. (Oxf) 2003;59(1):115-28.
- Fougner S.L., Borota O.C., Berg J.P., Hald J.K., Ramm-Pettersen J., Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. (Oxf) 2008;68(3):458-65.
- Katznelson L., Laws E.R., Melmed S., Molitch M.E., Murad M.H., Utz A., Wass J.A.; Endocrine Society. Acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014;99(11):3933-51.
- Bevan J.S., Newell-Price J., Wass J.A., Atkin S.L., Bouloux P.M., Chapman J., Davis J.R., Howlett T.A., Randeva H.S., Stewart P.M., Viswanath A. Home administration of lanreotide autogel by patients with acromegaly, or their partners,is safe and effective. Clin. Endocrinol. (Oxf) 2008;68:343-49.
- Salvatori R., Woodmansee W.W., Molitch M., Gordon M.B., Lomax K.G. Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary. 2014;17:13-21.
- Schopohl J., Strasburger C.J., Caird D., Badenhoop K., Beuschlein F., Droste M., Plöckinger U., Petersenn S.; German Lanreotide Study Group. Efficacy and acceptability of lanreotide autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes. 2011;119:156-62.
- Johanson V., Wilson B., Abrahamsson A., Jianu C., Calissendorff J., Wall N., Gronbæk H., Florholmen J., Ohberg A., Granberg D. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional. Patient Prefer Adherence. 2012;6:703-10.
- Анциферов М.Б., Пронин В.С., Алексеева Т.М. Медикаментозное лечение пациентов с акро мегалией, частично резистентных к терапии аналогами соматостатина. Фарматека. 2011;16:49-55.
- Andries M., Glintborg D., Kvistborg A. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. (Oxf) 2008;68(3):473-80.
- Ronchi C.L., Boschetti M., Degli Uberti E.C., Mariotti S., Grottoli S., Loli P., Lombardi G., Tamburrano G., Arvigo M., Angeletti G., Boscani P.F., Beck-Peccoz P., Arosio M.; Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicenter longitudinal study. Clin. Endocrinol. (Oxf) 2007;67(4):512-19.
- Neggers S., Pronin V., Balcere I. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur. J. Endocrinol. 2015;173:313-32.
- Bevan J.S., Newell-Price J., Wass J.A., Atkin S.L., Bouloux P.M., Chapman J., Davis J.R., Howlett T.A., Randeva H.S., Stewart P.M., Viswanath A. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf) 2008;68(3):343-49.
Supplementary files
